Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

by @JTC_PALIdev | Dec 30, 2022 | Press Releases

Carlsbad, CA, Dec. 30, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with...

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

by @JTC_PALIdev | Dec 16, 2022 | Press Releases

Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing...

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

by @JTC_PALIdev | Dec 7, 2022 | Press Releases

Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today...

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

by @JTC_PALIdev | Dec 1, 2022 | Press Releases

Carlsbad, CA, Dec. 01, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that on December 1, 2022, it received notice from The...

Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery

by @JTC_PALIdev | Nov 22, 2022 | Press Releases

Carlsbad, CA, Nov. 22, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic post-surgical complications following gastrointestinal (GI) surgery, today announced that the U.S....

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

by @JTC_PALIdev | Nov 18, 2022 | Press Releases

Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 – serving as recent expert clinical advisor to Palisade Bio Carlsbad,...